GMTX insider filings
Gemini Therapeutics, Inc. /DE — 36 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-10-27. Screen GMTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for GMTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Gemini Therapeutics, Inc. /DE
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-10-27 | 4 | Leonard Braden Michael — 10% owner | Sale (S): 22,500 @ $2.09 | EDGAR |
| 2022-06-02 | 4 | Piekos Brian — CFO | Grant/award (A): 9,960 @ $1.09 | EDGAR |
| 2022-04-13 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 55,000 @ $1.36 · Purchase (P): 504,487 @ $1.35 · Purchase (P): 203,744 @ $1.42 · Purchase (P): 191,769 @ $1.52 | EDGAR |
| 2022-03-09 | 4/A | Ong Tuyen — Director | Grant/award (A): 15,528 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4/A | Lubner David Charles — Director | Grant/award (A): 17,529 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4/A | Lubner David Charles — Director | Grant/award (A): 0 (derivative) @ $0 | EDGAR |
| 2022-01-14 | 4 | Piekos Brian — CFO | Grant/award (A): 280,876 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Meyenburg Jason Patrick — Chief Executive Officer, Director | Grant/award (A): 123,600 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | GEMAYEL GEORGES — Executive Chair of the Board, Director | Grant/award (A): 793,274 (derivative) @ $0 | EDGAR |
| 2021-11-16 | 4 | GEMAYEL GEORGES — See Remarks, Director | Grant/award (A): 23,514 (derivative) @ $0 · Grant/award (A): 17,245 (derivative) @ $0 | EDGAR |
| 2021-10-20 | 4 | Piekos Brian — Chief Financial Officer | Grant/award (A): 90,720 (derivative) @ $0 | EDGAR |
| 2021-10-06 | 4 | Ong Tuyen — Director | Grant/award (A): 17,245 (derivative) @ $0 | EDGAR |
| 2021-10-06 | 4 | Tananbaum James B. — Director, 10% owner | Grant/award (A): 17,245 (derivative) @ $0 | EDGAR |
| 2021-10-06 | 4 | Rhodes Jason P — Director, 10% owner | Grant/award (A): 17,245 (derivative) @ $0 | EDGAR |
| 2021-10-06 | 4 | Lubner David Charles — Director | Grant/award (A): 17,245 (derivative) @ $0 | EDGAR |
| 2021-10-06 | 4 | GORDON CARL L — Director, 10% owner | Grant/award (A): 17,245 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Piekos Brian — Chief Financial Officer | Purchase (P): 7,655 @ $9.46 | EDGAR |
| 2021-05-18 | 4 | Meyenburg Jason Patrick — President & CEO, Director | Purchase (P): 13,000 @ $9.46 | EDGAR |
| 2021-05-03 | 4 | Strapps Walter — Chief Scientific Officer | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2021-05-03 | 4 | GEMAYEL GEORGES — Director | Grant/award (A): 45,466 (derivative) @ $0 | EDGAR |
| 2021-04-14 | 4 | Piekos Brian — Chief Financial Officer | Grant/award (A): 377,734 (derivative) @ $0 | EDGAR |
| 2021-04-14 | 4 | Barone Samuel B. — Chief Medical Officer | Grant/award (A): 255,212 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Strapps Walter — Chief Scientific Officer | Grant/award (A): 79,094 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Uknis Marc — Chief Medical Officer | Grant/award (A): 277,117 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Redmond Precillia — Chief People Officer | Grant/award (A): 77,450 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Lauder Scott — Chief Technology Officer | Grant/award (A): 243,996 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Meyenburg Jason Patrick — President & CEO, Director | Grant/award (A): 1,124,832 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Ong Tuyen — Director | Grant/award (A): 58,855 (derivative) @ $0 | EDGAR |
| 2021-04-07 | 4 | Lubner David Charles — Director | Grant/award (A): 58,855 (derivative) @ $0 | EDGAR |
| 2021-03-15 | 4 | Ong Tuyen — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-03-15 | 4 | Lubner David Charles — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Strapps Walter — Chief Scientific Officer | Grant/award (A): 99,133 (derivative) @ $0 | EDGAR |
| 2021-02-25 | 4 | Redmond Precillia — Chief People Officer | Grant/award (A): 25,489 (derivative) @ $0 | EDGAR |
| 2021-02-25 | 4 | Lauder Scott — Chief Technology Officer | Grant/award (A): 272,615 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | FS Development Holdings, LLC — 10% owner Foresite Capital Fund V, L.P. — 10% owner Foresite Capital Management V, LLC — 10% owner Foresite Capital Opportunity Fund V, L.P. — 10% owner Foresite Capital Opportunity Management V, LLC — 10% owner | Grant/award (A): 1,500,000 @ $10 · Conversion (C): 2,928,750 @ $0 · Conversion (C): 2,928,750 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | Tananbaum James B. — Director | Grant/award (A): 1,500,000 @ $10 · Conversion (C): 2,928,750 @ $0 · Conversion (C): 2,928,750 (derivative) @ $0 | EDGAR |
Recent 8-K events — Gemini Therapeutics, Inc. /DE
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | ? | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GMTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs